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Overall survivalAlthough numerous studies highlighted the role of Epstein–Barr Virus (EBV) in B-cell transformation, the
involvement of EBV proteins or genome in the development of the most frequent adult leukemia, chronic
lymphocytic leukemia (CLL), has not yet been defined. We hypothesized that EBV microRNAs contribute to
progression of CLL and demonstrated the presence of EBVmiRNAs in B-cells, in paraffin-embedded bonemarrow
biopsies and in the plasma of patients with CLL by using three different methods (small RNA-sequencing,
quantitative reverse transcription PCR [q-RT-PCR] and miRNAs in situ hybridization [miRNA-ISH]). We found
that EBV miRNA BHRF1-1 expression levels were significantly higher in the plasma of patients with CLL
compared with healthy individuals (p b 0 · 0001). Notably, BHRF1-1 as well as BART4 expression were detected
in the plasma of either seronegative or seropositive (anti-EBNA-1 IgG and EBV DNA tested) patients; similarly,
miRNA-ISH stained positive in bone marrow specimens while LMP1 and EBER immunohistochemistry failed to
detect viral proteins and RNA. We also found that BHRF1-1 plasma expression levels were positively associated
with elevated beta-2-microglobulin levels and advanced Rai stages and observed a correlation between higher
BHRF1-1 expression levels and shorter survival in two independent patients' cohorts. Furthermore, in themajor-
ity of CLL cases where BHRF1-1 was exogenously induced in primary malignant B cells the levels of TP53 were
reduced. Our findings suggest that EBV may have a role in the process of disease progression in CLL and that
miRNA RT-PCR and miRNAs ISH could represent additional methods to detect EBV miRNAs in patients with CLL.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).competing financial interest.
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Over the past decade, numerous studies have highlighted the central
role of short non-coding transcripts, named microRNAs (miRNAs),
in the pathogenesis of CLL and their influence on the development of
the disease and its aggressiveness (Fabbri et al., 2011). MiRNAs are
non-coding RNAs which target messenger RNA for degradation andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pathologic processes (Calin and Croce, 2009). Amodel of CLL pathogen-
esis that accounts for three of themost frequent recurrent chromosomal
abnormalities in B-CLL (13q-, 11q- and 17p-) has been developed
explaining the complex interaction networks composed of coding and
non-coding genes (Fabbri and Croce, 2011).
The clinical course of CLL is highly heterogeneous; some patients
have indolent disease never requiring treatment, whereas others need
treatment at the time of disease presentation. Several prognostic
markers have been identified including genomic abnormalities accord-
ing to fluorescent in situ hybridization (FISH) (Dohner et al., 2000),
immunoglobulin heavy chain variable gene (IGHV) mutation status
(Hamblin et al., 1999; Damle et al., 1999), CD38 (Damle et al., 1999)
and ZAP70 expression (Crespo et al., 2003). The prognostic value of
biological markers relies on the ability to predict time to first treatment,
response to treatment, progression free survival and overall survival
(OS). Recently, our group found that a microRNA, miR-155, was
expressed at high levels in B-cells from patients with CLL compared
with B-cells from normal individuals and in plasma of patients who
failed to achieve a complete response compared to responding patients,
suggesting its role as a biomarker for risk of progression (Ferrajoli et al.,
2013).
Several studies have investigated the role played by the Epstein–Barr
Virus (EBV) and other viruses in the pathogenesis of CLL (Tsimberidou
et al., 2006; Tarrand et al., 2010), but a definitive mechanism involving
EBV proteins or genome has not been identified. EBV is a ubiquitous,
human-specific gamma herpes virus, which typically causes subclinical
and latent infection of B cells in healthy individuals. It is associated with
a variety of B-cell lymphomas that arise in patients with or without
overt impairments in cellular immunity (Campo et al., 2011). Interest-
ingly, in EBV-associated lymphomas, the substantial majority of cells
show evidence for the presence of EBV genome by in-situ hybridization
(ISH) (Delecluse et al., 2007). Three types of EBV latency states have
been described in EBV-related lymphomas according to the pattern of
EBV nuclear antigen (EBNA) and the latent membrane protein (LMP)
expression. Two sets of non-coding RNAs are also expressed in all
forms of EBV infection: the EBER RNAs (Arrand and Rymo, 1982;
Lerner et al., 1981) and the BamHI A rightward transcripts (BARTs). It
has been shown that EBV also encodes miRNAs (Cai et al., 2006). EBV
miRNAs map to two regions of the viral genome: BHRF1 miRNAs are
located immediately upstream and downstream of the BHRF1 open
reading frame, while BART miRNAs lie within the intronic regions of
BART genes (Amoroso et al., 2011). To date there is little information
regarding their functions in the viral and cell life cycle although some
specific targets have been identified (Marquitz et al., 2011; Dolken
et al., 2010; Barth et al., 2008; Choy et al., 2008; Lo et al., 2007; Lung
et al., 2009; Xia et al., 2008). EBV infectionmay influence the expression
of several cellular miRNAs (Navarro et al., 2008). Interestingly, it has
been reported that miR-155 is the cellular miRNA most highly induced
after EBV infection of lymphoblastoid B-cells (Linnstaedt et al., 2010).
The purpose of our study is to assess EBV miRNAs expression and
their contribution to the CLL disease progression. To do this, we ana-
lyzed by different methods (small RNA sequencing analysis, qRT-PCR
and miRNA In Situ Hybridization) the expression levels of EBV miRNAs
in B-cells, plasma and paraffin-embedded bone marrow biopsy
specimens from patients with CLL and determined their association
with clinical outcome.2. Material and Methods
2.1. Patients and Samples
A total of 516 samples obtained from patients evaluated at the
University of Texas MD Anderson Cancer Center, Houston, Texas
(UTMDACC) and The Mayo Clinics, Rochester, Minnesota were usedfor this study (Table S1). Informed consent was obtained per institu-
tional guidelines and in accordance with the Declaration of Helsinki.
We initially analyzed 48 samples by small RNA sequencing, including
B-cells isolated from 34 patients with CLL and 14 healthy individuals.
Subsequently, we performed quantitative reverse transcriptase PCR
(qRT-PCR) using the training/validation approach with multiple sets
of B-cells and plasma samples. The samples were divided as follows:
i) B-cells collected from 93 patients with untreated CLL constituted the
training group and; ii) B-cells from a second set of 54 patients with
both treated and untreated patients constituted the validation group
(clinical characteristics of these patients were described in Rossi et al.)
(Rossi et al., 2010); iii) normal B lymphocytes from 20 healthy individ-
uals were used as normal controls. Plasma samples collected from the
following groups: i) plasma samples from 143 patients with untreated
CLL constituted the training set; ii) plasma samples from a second set
of 49 patientswith CLL constituted the validation set; iii) plasma samples
from 80 healthy individuals were used as normal controls. Finally, we
performed miRNA In Situ Hybridization (miRNA ISH) on paraffin-
embedded bone marrow biopsies obtained from 29 patients with CLL,
(with 19 out of 29 arranged on a Tissue Micro Array (TMA)). None of
the CLL patients were on immunosuppressive therapy before the sam-
ples collection. The B-cells and the plasma samples in the training cohort
were collected from previously untreated patients. Although the B-cells
validation cohort included both treated and untreated patients, none of
the samples were collected during treatment.
Healthy individuals were volunteer blood donors; here “healthy”
was defined as the absence of any type of cancer or known medical
condition at the time of the sample collection has previously reported
(Zuo et al., 2011).
Patients with CLL had a confirmed diagnosis based on morphologic
and immunophenotypic features, and they were staged according to
the Rai classification. Immunoglobulin heavy chain variable (IGHV)
gene mutational analysis, zeta-chain associated protein kinase 70 kDa
(ZAP70) status, CD38 status and fluorescence in situ hybridization
(FISH) analysis were available for most of the patients. IGHV mutation
was defined by the presence of b98% homology at sequencing and
ZAP70 was defined as being positive if expressed in more than 20% of
cells by flow cytometry. The characteristics of the patients are summa-
rized in Table 1.
B-cellswere isolated and/or purified fromblood samples of healthy in-
dividuals and patients with CLL as previously described (Ferrajoli et al.,
2013). The typical purity of CD19+ CLL cells for our studies was N90%.
Plasma samples were obtained from the CLL Research Consortium
bank at The University of California, San Diego where they had been
stored at−80 °C until the experiments were performed.
2.2. Small RNA Sequencing
RNAwas extracted with Trizol Reagent (Life Technologies, Carlsbad,
CA) and the SOLiD Total RNA-Seq kit was used for the library prepara-
tion (Life Technologies, Carlsbad, CA). The RNA was run on the SOLiD
5500XL System (Applied Biosystems, Carlsbad, CA). We analyzed the
miRNA-sequencing data using CLC Genomics Workbench 6 using
default parameters and obtained miRNA sequences from miRBase. In
the analysis, after filtering those reads that mapped to human miRNAs,
the remaining reads were mapped to various viruses of interest.
Sequences for miRNAs of 27 different viruses were obtained from the
miRBase database (release 20, June 2013, www.mirbase.org). The
match types of mapped reads were annotated according to the location
within miRNA genes by the software.
2.3. B-cell RNA Isolation, miRNA Expression Analysis and Normalizer
Identification
RNA was extracted with Trizol (Life Technologies, Carlsbad, CA)
using B-cells isolated from healthy donors, or patients with CLL.
Table 1
Clinical characteristics of patients with CLL.
CLL B-cells Plasma
Characteristics (Training set)
(n = 93)
(Validation set)
(n = 54)
CLL
(n = 143)
No. (%) No. (%) No. (%)
Rai stage
0–2 79 (85) 26 (72) 106 (74)
3.–4 14 (15) 10 (28) 37 (26)
No data 18
ZAP70 expression
Positive 27 (39) 34 (63) 74 (54)
Negative 43 (61) 20 (37) 64 (46)
No data 23 5
CD38 expression
Positive 25 (27) 20 (37) No data
Negative 68 (73) 34 (63)
FISH results
Negative 14 (16) 19 (45) 19 (26)
13q deletion 43 (51) 2 (5) 14 (19)
Trisomy 12 19 (22) 0 (0) 9 (12)
11q deletion 2 (2) 0 (0) 24 (33)
17p deletion 6 (7) 21 (50) 7 (10)
Other 1 (1) 0 (0) 0
No data 8 12 70
IGHV mutation status
Mutated 56 (63) 14 (26) 36 (27)
Unmutated 33 (37) 31 (57) 99 (73)
No data 4 9 8
Median time to treatment
(months) (range)
79.7 (0–124.94) 19 (0.07–190.49)
Abbreviations: CLL, chronic lymphocytic leukemia; FISH, fluorescence in situ hybridization;
IGHV, immunoglobulin heavy chain mutational status.
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method (Life Technologies, Carlsbad, CA), with a CFX384 real-time
PCR detection system (Biorad, Hercules, CA). Briefly, 10 ng of total
RNA was reverse transcribed using the miRNA reverse transcription
kit (Life Technologies, Carlsbad, CA) and a specific reverse-
transcription stem-loop primer, according to the manufacturer's proto-
col. Expression levels for the normalizer 5Sr RNAwere measured by the
SYBR Green method (Bio-Rad-SsoFast, Hercules, CA) and were similar
for all groups of samples (Fig. S2). Reverse transcription reaction was
performed on 10 ng total RNA of each patient sample with random
hexamers using SuperScript III First-Strand Synthesis System (Life Tech-
nologies, Carlsbad, CA), according to the manufacturer's instructions.
Real-time qPCR analysis was performed using the gene-specific Taqman
assay (primers and probes; Life Technologies, Carlsbad, CA) and SYBR
Supermix (BioRad, Hercules, CA), according to the manufacture's
protocol.
2.4. Plasma RNA Isolation, miRNA Expression Analysis and Normalizer
Identification
RNA isolationwas performed on 100 μl of stored plasma collected on
citrate with Norgen kit (Norgen Biotek, Thorold, Canada); the RNA
extraction from the CLL plasma was performed by using Trizol reagent
(Life Technologies, Carlsbad, CA). MiRNA expression was measured
with the TaqMan miRNA qRT-PCR methods (Life Technologies,
Carlsbad, CA) and all reactions were run in duplicate. The expression
of a miRNA relative to the endogenous control miR-16 was determined
using the 2−ΔCt method (fold change). If expression values for
the endogenous control or for a specific miRNA were not obtained
after 40 cycles of amplification in two successive experiments in dupli-
cate wells, then the specific values were considered unavailable.Expression levels for miR-16 were similar for all groups of plasma
samples (Fig. S3).
2.5. EBNA-1 IgG Enzyme-Linked Immuno Sorbent Assay (ELISA)
In order to verify the EBV serological status of healthy individuals
and patients with CLL, the EBNA-1 IgG ELISA assay was performed
on plasma samples according to manufacturer's instructions (Fisher
Scientific, Carlsbad, CA). Briefly, the 96-well Diamedix ELISA plates
were coated with purified recombinant (E. coli as vector) EBNA-1 anti-
gen. Plasma from patients, healthy individuals, negative and positive
controls was diluted 1:21 in a phosphate buffer. The plateswere treated
with goat-anti-human IgG linked to horseradish peroxidase (HRP) and
colorwasdevelopedwith 3, 3′, 5, 5′ tetramethylbenzidine TMB solution.
The optical density (OD) was read at 450 nm within 60 min from the
completion of the reaction.
The cut-off calibrator, a blank sample, the positive and the negative
controls were included in each test run. The cut-off calibrator was run
in triplicate. The OD450 index value of each well was calculated as the
ratio between absorbance of the sample and mean absorbance of the
cut-off calibrator according to the manufacturer's instructions.
2.6. EBV-DNA Quantitative PCR
DNA was extracted from 143 CLL patients with the QIAamp® DNA
Mini Kit (Qiagen, ND). Quantitative end point PCR was performed on
8 ng of DNA, using the SsoFast Universal Probe Mix (Bio-Rad, Hercules,
CA) in a CFX384 Real-Time System (BioRad, Hercules, CA) according to
the manufacturer's instructions. The following primers and probes
were used: Primer EBV W-F: GCA-GCC-GCC-CAG-TCT-CT, Primer EBV
W-R: ACA GAC AGT GCA CAG GAG CCT, Probe EBV BamHIW:
6FAMAAAAGCTGGCGCCCTTGCTAMRA. Endpoint analysis was carried
out with the CFX Manager Software (v3.1) (BioRad, Hercules, CA)
with the followingparameters: 2 end cycles to average and a percentage
of range of−10. The Applied BiosystemsTaqMan® Exogenous Internal
Positive Control (Life Technologies, Carlsbad, CA) was used as an inter-
nal control to distinguish true negative results from PCR inhibition
according to the manufacturer's recommendations. Samples were
determined to be positive for EBV DNA expression if the RFU exceeded
the cut-off of 249 RFU, which was determined by the CFX Manager
Software.
2.7. MiRNA In Situ Hybridization (miRNA ISH) and Immunohistochemistry
The miRNA-ISH was carried out as reported elsewhere (Nishimura
et al., 2013). Briefly, double digoxigenin labeled locked nucleic
acid probes antisense to BHRF1-1 and miR-155 (Exiqon, Vedbaek,
Denmark) (Fig. S4) were hybridized on tissue sections for 3 h at 55 °C.
Detection was accomplished with anti-DIG alkaline phosphate Fab
fragment followed by nitro blue tetrazolium chloride/5-bromo-4-
chloro-3-indolyl phosphate (NBT/BCIP) color development (Ventana,
Roche, Basel, CH). Each case was tested for U6 probe reactivity as a
positive control and the U6 staining was used as normalizer. The
scrambled-miRNA probe (Exiqon Vedbaek, Denmark) was chosen as a
negative control for staining.
Additionally, standard ISH for EBER-1 was performed using INFORM
probes (Ventana, Roche, Basel, CH) according to the manufacturer's
protocol. To detect LMP-1, paraffin-embedded sections were treated
with ER1 citrate buffer (pH, 6.0) for 5 min at 100 °C and incubated
with diluted primary mouse monoclonal antibody CS1-4 (anti-LMP-1;
Dako, Glostrup, Denmark). For detection, the sections were treated
with poly HRP anti mouse and anti-rabbit IgG secondary antibodies
(BioRad, Hercules, CA) after treatment with 0.1 mol/L citrate buffer
(pH, 6.0) for 7 min at 120 °C.
For EBER ISH, cases were scored as positive when nuclei showed
positivity that was absent in the negative control. A positive control
575A. Ferrajoli et al. / EBioMedicine 2 (2015) 572–582was included in each experiment. Positivity for LMP-1 was defined by
the detection of immunoreactivity that was not present in the negative
control.
2.8. Construction of BHRF1-1 Lentivirus, Infection of Primary Malignant B
Cells from CLL Patients and TP53 Measurement by Western Blot
We constructed a lentivirus expressing BHRF1-1, the pMIRNA1–
BHRF1-1 and the pMIRNA1–Empty Vector provided in E. coli bacterial
stock form plated on LB-carbenicillin at 50 μg/ml (System Biosciences).
The viral particles were obtained with the protocol from the System
Biosciences User Manual, using the 293-TN cell line and pPACKH1
Lentivector Packaging Kit (System Biosciences). Virus pellets were
resuspended in DMEM and stored in cryovials at−80 °C until use.
Primary malignant B cells from serial patients with CLL collected
before treatment in the Leukemia Department at MD Anderson Cancer
Center were infected with the pMIRNA1–BHRF1-1 lentivirus with an
efficiency of approximately 50% as determined by green fluorescent
protein measurement by flow cytometry. Empty lentivirus (LVEV,
lentivirus empty vector) was used as a negative control for the
experiments.
After 96 h from infections, the protein extracts were prepared in ice-
cold RIPA lysis buffer 1× (Santa Cruz Biotechnology) containing
phenylmethylsulfonyl fluoride (PMSF), sodium orthovanadate and
protease inhibitor cocktail, or in 1× Lysis buffer (Cell Signaling) supple-
mented with protease and phosphatase inhibitor (Sigma-Aldrich)
according to the manufacturer's instructions.
Total protein (50 μg) was electrophoresed on Criterion TGX Stain
Free Precast Gels (Bio-Rad Laboratories) and electroblotted onto pure
PVDF or nitrocellulose membranes (Trans-Blot Transfer Turbo midi-
format 0.2 μm; Bio-Rad Laboratories) with the Trans Blot Turbo System
(Bio-Rad Laboratories). Membrane blocking and antibody incubation
were performed according to the Cell Signaling Western Immunoblot-
ting Protocol, and antigen–antibody reactions were detected with
SuperSignal West Femto reagents (Thermo Scientific). We used
the primary antibodies anti-TP53DINP1 rabbit polyclonal antibody
(OriGene) and the anti-Actine antibody as normalizer.
2.9. Statistical Analysis
All statistical analyses were performed in R (version 3.0.1). All tests
were two-sided and considered statistically significant at the 0.05
level. The Shapiro–Wilk test was applied to determine whether
data followed a normal distribution. The t-test or analysis of variance
followed by the post-hoc Tukey test (depending on the number of
groups considered) was applied to normally distributed data;
otherwise, the Mann–Whitney–Wilcoxon test or Kruskal–Wallis test
followed by a post-hoc Nemenyi test was applied to assess the relation-
ship betweenmiRNA expression and clinical parameters. The Spearman
correlation test was applied to measure the strength of the association
between the variables. For each cohort, we checked for a relationship
between miRNA expression and overall survival as follows. Patients
were grouped into percentiles according to miRNA expression. The
Log-rank test was employed to determine the association between
miRNA expression and overall survival (OS). The Kaplan–Meiermethod
was used to generate OS curves. The cut-off to optimally separate the
patients into low/high miRNA (log-rank test p-value minim) was cho-
sen. The relationship between OS and covariates (miRNA expression
levels and known prognostic factors or other clinical parameters, such
as CD38, IGVH mutation status and ZAP70 expression) was examined
using a Cox proportional hazard model. Neither FISH (high rate of
missing data) nor Rai stage (few cases in the high risk group) were
considered in the models. Only the factors that were statistically
significant via univariable regression analyses were included in the
final multivariable regression model.3. Results
3.1. Small RNA-sequencing and qRT-PCR Identified EBV miRNAs Expression
in Peripheral Blood B-cells
By small RNA-sequencing we identified the presence of EBVmiRNAs
in themalignant CLL B-cells (n=34 samples) aswell as in normal B-cells
(n = 14 samples) (Fig. 1A–B). Sixteen different viruses out of twenty-
seven screened, were found by small-RNA sequencing (Fig. 1C). The
vast majority (97%) of viral reads were from herpes gamma virus (EBV
and Rhesus lymphocryptovirus). In order to confirm the sequencing
results, we performed qRT-PCR on 12 samples (8 patients with CLL and
4 healthy individuals) and 3 EBV-positive cell lines (MEC1, MEC2 and
Raji) as controls. The expression of 26 different EBV miRNAs, including
the miRNAs identified by small RNA sequencing, was evaluated
(Table S2 and Fig. S1). We found that BART-4 and BHRF1-1 miRNAs
were expressed both in small RNA sequencing and at less than
35 cycles in qRT-PCR (mean cycle threshold [Ct] in CLL samples 25.16,
SD = 1.08 and 34.1, SD = 2.09 respectively) and further focused on
the study of these two EBV miRNAs.
3.2. 5S rRNA in B-cells and miR-16 in Plasma Showed Stable Expression in
Normal Individuals and Patients with CLL
We then tested the levels of various non-coding RNAs as normalizer
including U6 snRNA, U18 snRNA, U48 snRNA, 5S rRNA and 18S rRNA, as
previously described (Ferrajoli et al., 2013). Among them, 5S rRNA
showed the most stable expression comparing normal and CLL B-cells,
both in training and validation sets (Fig. S2) and therefore we decided
to use this as the reference gene. For the plasma analysis, we initially
performed qRT-PCR to amplify 2 genes previously used as normalizers
in prior studies we conducted using plasma, miR-192 and miR-16
(Cortez et al., 2011; Pritchard et al., 2012; Vasilescu et al., 2009). Mir-
16 was expressed at high levels in all samples (mean Ct = 25.4, SD =
1.68), whereas miR-192 was expressed at low levels in about 86% of
samples (mean Ct = 33.19, SD= 1.20). However, the miR-16 chromo-
somal locus (13q14) is deleted or silenced in a consistent proportion of
patients with CLL. As we previously published (Ferrajoli et al., 2013), in
order to confirm the validity of miR-16 as normalizer we analyzed the
miR-16 expression levels between cytogenetic subgroups; in our
cohort, no significant differences were observed, depending on FISH
abnormalities. These results allowed us to use miR-16 as the sole nor-
malizer according to the published qRT-PCR MIQE guidelines (Fig. S3)
(Bustin et al., 2009).
3.3. BHRF1-1 miRNA is Expressed at High Level in Plasma of Patients with
CLL and Positively Correlated with miR-155 Expression
The plasma levels of amiRNAmight not be proportional to the B-cell
expression levels because miRNAs are secreted by various cells, includ-
ingmalignant or microenvironment cells. We previously reportedmiR-
155 overexpression in the plasma of patients with CLL and its correla-
tion to a poor response to therapy (Ferrajoli et al., 2013). Thus, to verify
if EBV miRNAs are also detectable in the plasma of patients with CLL,
we extended the analysis of the two previously chosen viral miRNAs
(BART4 and BHRF1-1) to plasma samples from 143 patients with CLL
(none of themwere on any treatment that could explain an EBV reacti-
vation) and 80 normal individuals. We measured BHRF1-1 relative
expression levels in the plasma of patientswith CLL and normal individ-
uals and found that BHRF1-1was expressed at significantly higher levels
in the plasma of patients with CLL (Fig. 2). We, therefore, evaluated a
correlation between plasma BHRF1-1 miRNA levels and certain patient
clinical characteristics and found that higher BHRF1-1 levelswere associ-
ated with higher beta-2-microglobulin level (b3.3 versus N3.3 mg/L,
p = 0.0008) and more advanced Rai stages (Rai 3–4 versus Rai 0–2,
p = 0.001).
Fig. 2. BHRF1-1 relative expression levels in plasma of patients with CLL and normal indi-
viduals. BHRF1-1 levelsweremeasured in plasma of 143 patients with CLL. The expression
of BHRF1-1 relative to the endogenous control miR-16 was determined using the 2−ΔCt
method (fold change). BHRF1-1 levels are significantly higher in patients with CLL than
in normal individuals.
Fig. 1. Small RNA-sequencing data on B-cells from normal individuals and patients with CLL. Both in B-cells from normal individuals (A) and patients with CLL (B), more than 50% of reads
thatmapped to the viral genomeswere attributed to the EBV genome. A total of 21 EBVmiRNAswere foundwith BART9 being the highest expressed (3645 reads) to BART12 and BHRF1-1
the lowest ones (1 read). Reads from 15 viruses other than EBV were found by RNAseq (C).
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individuals and patients with CLL and found similar relative expression
levels between these two groups (p = 0.5933). We also evaluated the
expression levels of BART4 miRNA in B-cells and found a non-
significant trend for lower levels in B-cells between normal individuals
versus patientswith CLL (p=0.0856). Similarly, we foundnodifference
in BART4 expression in the plasma of normal individuals when
compared to the plasma of patients with CLL (p = 0.6849).
Because of the possible role of EBV genes in inducing miR-155 (Lu
et al., 2008), we compared miR-155, BART4 and BHRF1-1 expression
levels in B-cells and plasma.We found a highly significant positive asso-
ciation between miR-155 and BHRF1-1 expression levels in plasma of
patients with CLL (Spearman correlation coefficient 0.43, p b 0.0001).3.4. BHRF1-1 miRNA is Expressed in both EBNA-1 IgG Seronegative and
Seropositive Patients
Weevaluated evidence of prior EBV infection in patients and healthy
individuals using an established ELISA techniques used in clinical labo-
ratories, the EBNA-1 IgG ELISA. The presence of EBNA-1 IgG is usually
consistent with past infection and the majority of normal individuals
older than 40 years (89 · 5–100%) are positive for this specific antibody
(Rickinson, 2001). Among the previously described 143 untreated pa-
tients, the mean values for IgG, IgA or IgM were 725 (89–2190 mg/dL),
89 (7–561 mg/dL), and 51 (4–438 mg/dL) respectively. None of the
patients had ongoing infections at the time of sample collection and
all patients tested negative for active hepatitis B or C, HIV or HTLV infec-
tions. All but one healthy individual showed EBNA-1 IgG positivity
(OD450 nm N 1.10). Similarly, 6 out of 143 patients with CLL (4%)
were negative (OD450 nm b 0.9) and 6 (4%) revealed an equivocal
test result (OD450 nm ranging between 0.9 and 1.09) (Fig. 3A). Two
patients out of the six who were negative by EBNA-1 ELISA, had total
IgG levels below the lower normal value (570 and 252 mg/dL with
normal range between 624–1680 mg/dL).
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with the expression levels of viral miRNAs and whether the absence of
past infection by EBV could predict lower or absent expression of viral
miRNAs. Surprisingly, not only patients with positive EBNA-1 IgG, but
also patients with a negative or equivocal EBNA-1 IgG test were found
to express BHRF1-1 (EBNA-1 IgG negative cases, BHRF1-1mean expres-
sion levels = 30.99; SD = 1.33; equivocal cases, mean = 32.71; SD =
1.22; positive cases, mean = 32.65; SD = 1.78) (Fig. 3B). The finding
that BHRF1-1 is expressed also in samples from patients who tested
negative for EBV infection was confirmed in a second group of 46 pa-
tients with CLL (negative EBNA-1 IgG cases, mean BHRF1-1 expression
levels = 32.16, SD = 1.19; positive cases, mean = 33.5, SD = 1.58)
(Fig. S5). Furthermore, we found that patients who were negative or
equivocal for EBV infection expressed BART4, although there was no
significant difference among the three different groups (EBNA-1 IgG
negative cases, mean BART4 expression levels = 26.41; SD = 0.18;
EBNA-1 IgG equivocal cases, mean = 26.72; SD = 0.22; EBNA-1 IgG
positive cases, mean = 26.61, SD = 0.36 in group 1; EBNA-1 IgG
negative cases, mean BART4 expression levels = 29.25; SD = 0.65;50 100 150
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ig. 3. BHRF1-1 relative expression in plasma of patients with CLL according to EBNA-1 IgG status (A) and EBV-DNA qPCR (B). The ELISA assay is expressed inOD450 nm ratio (absorbance
f the sample/mean absorbance of the cut off calibrator) and the testwas considerednegative if theOD450 ratiowas less than 0.9 or positive for values greater or equal to 1 · 10. For OD450
tios between 0.9 and 1.09, the test was considered equivocal according tomanufacturer's instructions (A). Expression of BHRF1-1 and BART4was found in the plasma of patients with a
egative and equivocal test for EBV EBNA-1 IgG (C and D). The red dot in panel C and D localizes the patient 116 with the positive EBV-DNA test in the plot-graphs of miR BHRF1-1 and
ART4 plasma expression levels, showing the presence of these two miRNAs.F
o
ra
n
Bpositive, mean= 29.34, SD= 0.43 in group 2) (Figs. 3C and S5). All to-
gether, we identified plasma from 15 patients with CLL that when ELISA
results are negative or equivocal for the EBV infection, the qRT-PCR for
an EBV viral miRNA that has no homology with any human miRNA
and therefore cannot cross-hybridize with human miRNAs, show
detectable expression (EBNA-1 IgG negative cases, mean BHRF1-1
expression levels = 31.38; SD = 1.34; EBNA-1 IgG equivocal cases,
mean = 32.71; SD = 1.22 in group 1 plus 2; EBNA-1 IgG negative
cases, mean BART4 expression levels = 27.35; SD = 1.46; EBNA-1 IgG
equivocal cases, mean = 26.72; SD = 0.22 in group 1 plus 2).
Although none of the 143 patients had ongoing infections at the time
of sample collection, in order to exclude that the expression of EBV
miRNAs in patients with CLL could be determined by the occurrence
of “active” EBV infection and that the seronegativity for EBNA-1 IgG
was depending on a disease-related immunodeficiency, we performed
EBV-DNA q-PCR (Fig. 3D). All patients tested negative, with the
exception of one patient that had an EBV-viral load slightly above the
threshold. This patient had no clinical signs or laboratory signs of EBV
infection.
578 A. Ferrajoli et al. / EBioMedicine 2 (2015) 572–5823.5. MiRNA In Situ Hybridization (miRNA-ISH) Confirmed the Presence of
EBV miRNAs and miR-155 in Bone Marrow Cells of Patients with CLL
In view of the pattern of differential BHRF1-1 miRNA expression
among healthy donors and patients with CLL using qPCR and of the
significantly higher expression of BHRF1-1 in patients with no
apparent previous infection by EBV, we performed miRNA-ISH in
29 bone marrow biopsies from patients with CLL as an additional
validation method. Furthermore, we evaluated miR-155 by ISH
in the same bone marrow biopsy sample as we have previously
reported that miR-155 is expressed in patients with CLL (Ferrajoli
et al., 2013). U6 was chosen as normalizer as we expected to see no
variation in staining intensity because it is constitutively transcribed
in majority of human cells. The scrambled-miRNA probe was used
as a negative control. B-cells in all cases were found to be positive
for BHRF1-1 and miR-155 ISH with a more consistent positivity
for BHFR1-1 (twice stronger intensity compared with miR-155)
(Figs. 4 and S6 and S7).
In Hodgkin lymphoma, LMP-1 is as informative as EBER for deter-
mining if a given case is EBV related or not (Herbst et al., 1991). In our
series, although all cases were scored negative for EBER and LMP-1
according to standard criteria (data not shown), 2 out of the 10 cases
showed the presence of few positive cells for LMP-1 immunostaining;Fig. 4.MiRNA In Situ Hybridization (miRNA-ISH) and Immunohistochemistry (IHC) in bonemar
miRNA control probes (B), BHRF1-1 (C) and miR-155 (D) (Nikon Microphot-FXA, ×10
of Hematoxylin&Eosin and LMP-1 staining: the megakaryocyte, as well as scattered small mo
(blue arrow) (Olympus BX40, Hematoxylin&Eosin ×200 [panel G], LMP-1 immunostain with hand in one case, LMP-1 was identified in megakaryocytes (Figs. 4
and S8).
3.6. BHRF1-1 Relative Expression in B-cells is Associated with Unfavorable
Prognostic Markers and Shorter Overall Survival
In order to investigate the potential impact of BHRF1-1 on disease
evolution and progression, we wondered whether BHRF1-1 influenced
OS. In 93 patients with CLL (training set), overexpression of BHRF1-1
in B-cellswas associatedwith shorter OS (p=0.001, Fig. 5A). The ability
of BHRF1-1 expression in B-cells to predict outcome was also evaluated
in a separate group (validation set) of 54 patients.Within this cohortwe
confirmed that higher BHRF1-1 relative expression levels in B-cells
correlated with an inferior outcome (p = 0.0331, Fig. 5B).
Finally, IGHV, ALC, and relative expression of BHRF1-1 were the
statistically significant factors, from the univariate Cox proportional
hazards models, which were included in the final multivariate analysis
of OS. Patients with high BHRF1-1 expression levels had an increased
estimated risk of death when compared to those with low relative
expression (hazard ratio [HR] = 5.947; 95% confidence interval
[CI] = 1.86, 19.015, p = 0.002). Similar result was observed for IgVH
mutation status (HR = 3.22; 95% CI = 1.16, 8.91, p = 0.0342)
(Table 2) (Hamblin et al., 1999; Damle et al., 1999).row biopsies. The panel shows the results of in situ hybridizationwith U6 (A), scrambled-
0). BHRF1-1 ISH was diffusely positive (red arrows). E and F showed the results
nonuclear cells in the bone marrow show weakly positive immunoreactivity for LMP-1
ematoxylin counterstain ×400 [panel H]).
Fig. 5. Kaplan–Meyer survival curves in patients with CLL according to the relative expression levels of BHRF1-1. Patients with high relative expression levels (cut-offs = 0.58 and 0.31 in
the training and validation set, respectively) of BHRF1-1 in B-cells (red line) show a significantly shorter overall survival from those with low levels of BHRF1-1 (blue line) (p= 0.001 and
p = 0.03 in the training and in the validation set, respectively). The red and the blue values below the curves represent patients at risk at the specified time points.
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in most Cases
To start understanding the mechanisms that could explain the clin-
ical correlations with OS identified for BHRF1-1 miRNA, we performed
a literature search of proved protein coding targets and identified that
in nasopharyngeal cancer cells the TP53 tumor suppressor gene was
proved as a BHRF1-1 target (Li et al., 2012). This is of great interest, as
CLL cases with deletion of the chromosome 17 locus harboring TP53
are well known to have a significantly poorer survival respect to the
non-deleted cases (Calin and Croce, 2009; Fabbri and Croce, 2011).
Therefore, we infected the primary malignant B cells from patients
with CLL without TP53 deletion with a lentiviral construct expressing
BHRF1-1 and measured by Western blot the levels of TP53 protein. Of
note, by using a threshold of at least 20% variation, in ten out of the
seventeen (59%) analyzed cases we identified variable reduction in
the levels of TP53 protein, while in 4 cases we identified an increase
and in the remaining three no changes. This explains at least in
part, why in the majority of cases the poorer survival of CLL patients
correlates with high levels of BHRF1-1 miRNA (Figs. 6 and S9).4. Discussion
In this study, we show that the expression level of EBV BHRF1-1 in
patients with CLL was predictive of shorter OS. This predictive power
was retained even when common prognostic factors were included in
the multivariate analysis. We also confirmed the ability of BHRF1-1
expression levels to define outcome in a validation group of patientsTable 2
Cox Proportional Hazards Multivariate Regression analysis of overall survival in patients with C
Variable Univariate
HR (95% CI)
ZAP70 (positive vs negative) 0.56 (0.112, 2.76)
CD38 (positive vs negative) 0.97 (0.35, 2.73)
IGHV (UM vs M) 3.22 (1.16, 8.91)
ALC (maximum value) 1.01 (1.002, 1.015)
BHRF1-1 (high vs low (cut-off = 0.58)) 5.09 (1.67, 15.47)
Abbreviations: HR, Hazard Ratio; CI, confidence interval; UM, unmutated; M, mutated; ACL, abs
chain variable region.with relapsed CLL, which included patients with very high-risk disease.
Furthermore, BHRF1-1 plasma levels were associated with high tumor
burden markers, namely elevated beta-2-microglobulin and advanced
Rai stages suggesting a possible role of this non-human miRNA in the
events that lead to CLL progression.
We document the expression of EBV viralmiRNAs by three indepen-
dent methods, small RNA sequencing, qRT-PCR and miRNA-ISH in
malignant B cells, plasma and bone marrow biopsies of patients with
CLL. It is noteworthy that more than 90% of adults older than 40 years
are EBV positive (Rickinson, 2001).We also found that only one healthy
donor and 4% of patients with CLL had negative EBNA-1 IgG titers.
Furthermore, we observed that BHRF1-1 expression levels in plasma
from untreated CLL patients are significantly higher than in plasma of
healthy donors. This result is in apparent contradictionwith the absence
of similar findings in leukemic B-cells. However, EBV infects not only B
lymphocytes, but also epithelial cells, smooth muscle cells, T- and NK-
cells which can eventually release it into the plasma via microvesicles
(Jochum et al., 2012); this phenomenon is likely to explain the discrep-
ancy between plasma and B-cell expression levels in patients with CLL.
An alternative explanation is that malignant B cells are actively secret-
ing microvesicles and/or exosomes that contain viral miRNAs (Ghosh
et al., 2010). Interestingly, none of the seronegative (EBNA-1 IgG)
patients had an EBV-DNA load above the threshold of positivity,
suggesting that the presence of EBV-miRNAs could not be explained
by the onset of active infection and/or the absence of EBV-specific
immunoglobulin due to CLL-related defects of antibody response.
Another interesting finding of our study was that patients who
apparently did not experienced EBV infection express BHRF1-1 and
BART4 miRNAs. This finding was confirmed in two different groups ofLL according to BHRF1-1 expression levels in B-cells.
Multivariate
p-Value HR (95% CI) p-Value
0.4735
0.958
0.0246 3.63 (1.1, 11.99) 0.0342
0.0165 1.01 (0.998, 1.01) 0.2264
0.0041 5.947 (1.86,19.015) 0.0026
olute lymphocyte count; CLL, chronic lymphocytic leukemia, IGHV, immunoglobulin heavy
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showed a clear positivity for LMP-1 and EBER staining on their respective
bonemarrow specimens. LMP-1mRNA has been shown to be expressed
in a significant proportion of patients with CLL and to correlate with the
degree of bone marrow involvement (Tarrand et al., 2010). However,
unlike the study reported by Tarrand et al. where serum levels or
mRNA were measured, we evaluated LMP-1 expression by IHC directly
on bone marrow specimens. In addition, expression of BHRF1-1 and
miR-155 by miRNA-ISH was found diffusely positive in bone marrow
specimens from patients.
Based on our experience, the measurement of miRNAs (by RT-PCR
and/or miRNA-ISH) may represent a more sensitive method to detect
viral components compared with assays detecting viral proteins only
(ELISA and IHC). In order to exclude that the positive results could be
attributed to the presence of human miRNAs with a homologous
sequence, we performed a search within the NCBI database using the
BLAST algorithm and did not find a human miRNA with an identical
sequence for BHRF1-1. Next, we found a positive correlation in the
studied patients between the plasma levels of miR-155 and those of
BHRF1-1miRNA.Wehave previously reported thatmiR-155 is amarker
of the risk of progression from monoclonal B cell lymphocytosis (MBL)
to CLL and a predictor of response to treatment (Ferrajoli et al., 2013).
Although DNA sequences were previously identified in the plasma
of patients with various cancers, this is the first study to identify
an EBV-associated miRNA in the plasma of patients with CLL (Ghosh
et al., 2010). These findings support the possibility that EBV
miRNA(s) released by infected cells could be taken up by CLL cells or
other cells and affect the gene expression levels in the new “host”
cells. It is known that patients with CLL can produce microvesicles
(Jochum et al., 2012) aswell as exosomes (N Kay, personal communica-
tion) and have increased levels of microvesicles in their plasma. Our
findings support the possibility that leukemic B-cells can have effective
cross talk and exchange of cellular contents with other neighboring
cells. Furthermore, this potential interaction expands our understand-
ing of theway CLLmay be initiated: “latent” EBV-infected cells commu-
nicate with the surrounding cells and the microenvironment by
releasing pathogenetic viral miRNAs and induction of the expression
of miR-155 as well as other oncogenic cellular miRNAs that affect cellFig. 6. Examples of the levels of TP53 after infection of B cells from CLL patients with BHRF1-1 le
protein expression done with Adobe Photoshop CS6. The full set of data from the 17 analyzed
BHRF1-1 expression after infection are also presented.survival and apoptosis. Furthermore, cellular protein coding genes
such as TP53 are targets of EBV viral miRNAs. The fact that TP53
level is reduced after BFRF1-1 infection in primary culture of malignant
B-cells from the majority of cases but not in all, suggest that other
cancer genes involved in the BHRF1-1 signaling pathway have to be
identified. However several factors, other than miRNAs, could explain
the role of EBV in the pathogenesis of CLL. For example, in the elderly
a significantly greater frequency of EBV-specific CD8+ T-cells has
been noted along with a lower frequency of EBV antigen-specific
interferon-gamma-producing T-cells (Ouyang et al., 2003). Thus, it is
possible that an abnormal response to EBV stimuli favors a robust
burst of B clones that are EBV-driven, especially in an older individual.
Our observation that all thepatientswith CLL express EBVmiRNAs at
high levels and therefore experienced infection with the virus is an
interesting finding. The mechanism(s) behind this miRNA expression
are under evaluation in our laboratory and once deciphered will help
us to better understand the EBV viral cycle. Furthermore, if confirmed
in large prospective studies, our data will support the introduction in
clinical practice of miRNA-related EBV diagnostic tests.
In conclusion, the increased expression levels of specific EBV
miRNAs in patients with CLL and their correlation with survival suggest
a possible role of EBV miRNAs in CLL disease progression. The presence
of the EBV genome in cells other than B lymphocytes may explain the
discrepancy in relative expression of BHRF1-1 between B-cells and plas-
ma. Further studies are required to prospectively validate our findings
and to discover further targets of EBV miRNA in CD19/CD5 B-cells in
order to better define the molecular mechanism(s) through which
EBV miRNAs contribute to CLL.
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